Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 19,268 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the transaction, the general counsel now directly owns 72,250 shares of the company’s stock, valued at $601,120. This represents a 21.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT traded up $0.03 on Tuesday, reaching $8.37. The company’s stock had a trading volume of 393,567 shares, compared to its average volume of 564,733. The company has a 50-day simple moving average of $8.13 and a 200 day simple moving average of $7.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The company has a market cap of $509.30 million, a P/E ratio of -6.20 and a beta of 1.31. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter in the prior year, the business posted ($0.22) EPS. The company’s revenue was up 3.5% on a year-over-year basis. As a group, equities research analysts anticipate that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Institutional Trading of Health Catalyst

A number of institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC raised its stake in shares of Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after acquiring an additional 3,221,408 shares during the period. Millennium Management LLC grew its stake in shares of Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares during the last quarter. Nepsis Inc. grew its stake in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after buying an additional 851,448 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $6,858,000. Finally, Portolan Capital Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $5,402,000. 85.00% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Evercore ISI boosted their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. boosted their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Stephens increased their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Royal Bank of Canada upped their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.